Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3618-3627

  Uddin, Md Jashim ^a   Crews, Brenda C ^a   Blobaum, Anna L ^a   Kingsley, Philip J ^a   Gorden, D Lee ^b   McIntyre, J Oliver ^b   Matrisian, Lynn M ^b   Subbaramaiah, Kotha ^c   Dannenberg, Andrew J ^c   Piston, David W ^a   Marnett, Lawrence J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; DIMETHYL SULFOXIDE; FLUOROCOXIB; INDOMETACIN; REAGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER TISSUE; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; GENE DELETION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOLECULAR IMAGING; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CARRAGEENAN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FLUORESCENT DYES; HCT116 CELLS; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR IMAGING;

EID: 77951738107     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2664     Document Type: Article

References (39)

1. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-128 (Pubitemid 36098273)
2. Tanabe K, Zhang Z, Ito T, Hatta H, Nishimoto S. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments. Org Biomol Chem 2007;5:3745-3757 (Pubitemid 350115415)
3. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. The J Rheumatol 1997;49:15-19 (Pubitemid 27314722)
4. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23: 254-266 (Pubitemid 46206877)
5. Marnett LJ. The COXIB experience: a look in the rear-view mirror. Annu Rev Pharmacol Toxicol 2009;49:265-290
6. Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001;46:785-789
7. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188 (Pubitemid 24294584)
8. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-2559
9. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-855
10. Toyokuni T, Kumar JS, Walsh JC, et al. Synthesis of 4-(5-[18F] fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography. Bioorg Med Chem Lett 2005;15:4699-4702
11. Tanaka M, Fujisaki Y, Kawamura K, et al. Radiosynthesis and evaluation of 11C-labeled diaryl-substituted imidazole and indole derivatives for mapping cyclooxygenase-2. Biol Pharm Bull 2006; 29:2087-2094
12. Majo VJ, Prabhakaran J, Simpson NR, Van Heertum RL, Mann JJ, Kumar JS. A general method for the synthesis of aryl [11C]methylsulfones: potential PET probes for imaging cyclooxygenase-2 expression. Bioorg Med Chem Lett 2005;15:4268-4271
13. Prabhakaran J, Underwood MD, Parsey RV, et al. Synthesis and in vivo evaluation of [18F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide as a PET imaging probe for COX-2 expression. Bioorg Med Chem 2007;15:1802-1807.
14. Wuest F, Kniess T, Bergmann R, Pietzsch J. Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. Bioorg Med Chem 2008;16:7662-7670
15. Schuller HM, Kabalka G, Smith G, Mereddy A, Akula M, Cekanova M. Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention. Chem Med Chem 2006;1:603-610
16. de Vries EF, van Waarde A, Buursma AR, Vaalburg W. Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med 2003;44:1700-1706
17. de Vries EF, Doorduin J, Dierckx RA, van Waarde A. Evaluation of [11C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl Med Biol 2008;35:35-42.
18. de Vries EF. Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation. Curr Pharm Des 2006;12:3847-3856
19. Timofeevski SL, Prusakiewicz JJ, Rouzer CA, Marnett LJ. Isoform-selective interaction of cyclooxygenase-2 with indomethacin amides studied by real-time fluorescence, inhibition kinetics, and site-directed mutagenesis. Biochemistry 2002;41:9654-9662
20. Sacks PG, Parnes SM, Gallick GE, et al. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 1988;48: 2858-2866
21. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367: 243-249
22. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 1996;3:927-933
23. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648
24. Kurumbail RG, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 2001;11:752-760
25. Bhattacharyya DK, Lecomte M, Rieke CJ, Garavito RM, Smith WL. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem 1996;271:2179-2184
26. Kalgutkar AS, Crews BC, Rowlinson SW, et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiiflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 2000;97:925-930
27. Harman CA, Turman MV, Kozak KR, Marnett LJ, Smith WL, Garavito RM. Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-α-substituted indomethacin ethanolamides. J Biol Chem 2007;282:28096-28105
28. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-6711
29. Regier MK, DeWitt DL, Schindler MS, Smith WL. Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. Arch Biochem Biophys 1993;301:439-444
30. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolaterial release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997;94:657-662
31. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998;273:9886-9893
32. Mbonye UR, Wada M, Rieke CJ, Tang HY, Dewitt DL, Smith WL. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006;281:35770-35778
33. di Meglio P, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation. Arthritis and rheumatism 2005;52:951-958 (Pubitemid 40365119)
34. Sheng HM, Shao JY, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-2259 (Pubitemid 27203783)
35. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-324 (Pubitemid 20046457)
36. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111: 1134-1140 (Pubitemid 26327618)
37. 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809
38. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044
39. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt 2001;6:122-133 (Pubitemid 32546877)